

LTR Pharma Secures Exclusive US Pharmacy & Fulfilment Partner for ROXUS®

11 June 2026

Highlights

- **Binding term sheet executed with Strive Specialties Inc.**, establishing exclusive US pharmacy fulfilment rights for ROXUS®.
- **Provides access to additional healthcare provider and clinic networks**, supporting future commercial expansion.
- **Provides access to a multi-state 503A pharmacy platform** supporting national pharmacy fulfilment infrastructure.
- **Represents a key launch-readiness milestone** in LTR Pharma's US commercialisation strategy for ROXUS®.
- **Parties progressing definitive agreements** ahead of planned commercial launch activities.

LTR Pharma Limited (ASX:LTP) ("LTR Pharma" or "the Company") has executed a binding term sheet with Strive Specialties Inc. ("Strive Pharmacy"), a US personalised medicine and 503A pharmacy for ROXUS®. This establishes the US pharmacy fulfilment infrastructure required to supply ROXUS in the United States and represents a key launch-readiness milestone in LTR Pharma's commercialisation strategy for the world's largest erectile dysfunction market.

Under the arrangement, LTR Pharma is the product owner, intellectual property holder, and formulation supplier, while Strive Pharmacy provides the pharmacy fulfilment infrastructure that dispenses ROXUS prescriptions across LTR Pharma's US commercial channels. ROXUS will reach US consumers through a multi-channel commercialisation strategy incorporating telehealth, pharmacy fulfilment and healthcare provider networks. ROXUS is LTR Pharma's rapid-acting intranasal treatment for erectile dysfunction, supplied in the United States through the US Section 503A personalised medicine pathway. Its intranasal delivery differentiates it from oral PDE5 inhibitors and is well-suited to the on-demand way patients increasingly access treatment in this category.

The Strive Pharmacy arrangement materially advances LTR Pharma's US commercialisation strategy by securing pharmacy fulfilment infrastructure, expanding future patient access opportunities and reducing launch execution risk ahead of commercial launch.

Key Terms

The agreement is a binding term sheet, not a completed, unconditional supply and fulfilment agreement. Its binding elements include the exclusivity, confidentiality, non-circumvention, payment and service-level provisions. The broader commercial terms are to be negotiated in good faith and documented in Definitive Agreements within 30 days of the effective date, extendable once by a further 30 days by mutual agreement. If the Definitive Agreements are not executed within that period, the term sheet terminates, except for the surviving binding provisions, and exclusivity ends automatically.

- **Exclusivity:** Strive Pharmacy holds sole US 503A pharmacy and fulfilment rights for ROXUS for the term, subject to ongoing performance.
- **Term:** two-year initial term from Commercial Launch, with annual autorenewal unless either party elects not to renew.
- **Commercial channels:** ROXUS will be supplied through a multi-channel commercialisation strategy incorporating telehealth, pharmacy fulfilment and healthcare provider networks.
- **Commercial launch:** subject to completion of technology transfer and pharmacy onboarding, and satisfaction of launch-readiness conditions.

About Strive Pharmacy

[Strive Specialties Inc](#) (Strive Pharmacy) is a US-based personalised medicine and 503A pharmacy operating an established, multi-state platform across five US states, providing national pharmacy infrastructure with all 50 state licenses for the compounding, packaging, fulfilment and shipping of prescription treatments. Strive Pharmacy supports prescribers, clinics and telehealth providers through its pharmacy fulfilment infrastructure and established clinic and provider network. Under the proposed model, Strive Pharmacy will be responsible for the preparation, fulfilment, shipping, and related quality and supply chain operations for ROXUS.

LTR Pharma Executive Chairman, Lee Rodne, said:

"Executing this binding term sheet with Strive Pharmacy materially advances our US commercialisation strategy for ROXUS. Securing an experienced national pharmacy fulfilment partner is an important launch-readiness milestone and provides the operational infrastructure required to support commercial launch activities. Combined with our broader patient acquisition and market access initiatives, the arrangement supports LTR Pharma's planned multi-channel approach to commercialising ROXUS in the United States."

Strive Pharmacy President/Co-Founder, Michael Walker, said:

"We are excited to partner with LTR Pharma to support the introduction of ROXUS in the United States. ROXUS is an innovative addition to the men's health category and aligns well with Strive Pharmacy's focus on personalised medicine and patient-centric care. We look forward to working with the LTR Pharma team on launch readiness and the operational activities required to support patient access across the United States."



- ENDS -

This announcement has been approved by the Board of Directors.

Forward-looking statement

This announcement contains forward-looking statements, including in relation to the negotiation and execution of Definitive Agreements, the timing of Commercial Launch, the timing and achievement of launch-readiness conditions and the Company's commercial strategy. These statements are based on information currently available to the Company and involve known and unknown risks, uncertainties and assumptions, many of which are beyond the Company's control. Actual results may differ materially from those expressed or implied. The Company does not undertake to update any forward-looking statement except as required by law.

About LTR Pharma

LTR Pharma is a commercial-stage pharmaceutical company delivering innovative therapies to address significant unmet medical needs through its proprietary intranasal drug-delivery platform. The Company has successfully commercialised its rapid-acting treatment technology in Australia and is expanding access whilst advancing regulatory pathways in the US and other key markets.

LTR's lead products, **SPONTAN®** and **ROXUS®**, are fast-acting intranasal sprays for the treatment of erectile dysfunction, enabling onset of action in 10 minutes or less. Building on this proven technology, the Company is now advancing **OROFLOW®**, a novel intranasal spray under development for the treatment of Oesophageal Motility Disorders (OMD) – a debilitating group of conditions affecting swallowing function.

Through strategic partnerships, LTR Pharma is expanding its pipeline and global footprint to deliver differentiated, patient-centric treatments that enhance quality of life.

LTR Pharma Investor Centre

Stay informed with LTR Pharma's latest announcements and market updates by visiting our [Investor Centre](#) or scan the QR code.



For further information please contact:

Media enquiries
Haley Chartres
haley@hck.digital

Investor enquiries
Peter McLennan
investors@ltrpharma.com